# larA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *larA* gene encodes lactate racemase, a nickel-dependent enzyme crucial for interconverting L- and D-lactate, essential for cell wall biosynthesis and lactate utilization as a carbon source in various bacteria. - Its genomic organization often involves a conserved operon (e.g., *larB-E-A*) regulated by carbon catabolite repression (CCR) and oxidative stress response systems, ensuring expression only when metabolically advantageous. - The 3D structure reveals a unique fold with an N-terminal domain for cofactor assembly and a C-terminal TIM-barrel-like domain housing the active site, which utilizes a nickel-pincer cofactor for catalysis. - Clinical significance arises from *larA* mutations associated with antibiotic resistance, particularly daptomycin resistance in enterococci due to altered metabolic flux, and its role in biofilm formation and potential as a virulence factor. - Inhibition of LarA or its cofactor biosynthesis machinery represents a promising avenue for novel antimicrobial drug development, targeting essential bacterial metabolic pathways. - D-lactate produced by LarA can modulate host immune responses via GPR81 signaling, potentially contributing to immune suppression during bacterial infections and biofilm-associated pathologies. --- ## Executive Summary & Key Metadata The **larA** gene encodes a protein of significant interest in the context of microbial metabolism and antimicrobial resistance (AMR). While the specific locus has been characterized in various bacterial species, the designation "larA" most prominently refers to the **lactate racemase subunit A** (LarA), a nickel-dependent enzyme involved in the racemization of lactic acid enantiomers. This reaction is critical for the metabolism of certain bacteria, particularly in the context of the bacterial cell wall and biofilm formation. The enzyme catalyzes the interconversion of L-lactate and D-lactate, a process that is essential for the synthesis of the cell wall component, muramic acid, in some organisms and for the utilization of lactate as a carbon source in others. The clinical significance of larA is emerging, particularly in the context of **antimicrobial resistance** and **pathogenesis**. The enzyme's role in cell wall metabolism makes it a potential target for novel antimicrobial agents. Furthermore, variations in the larA gene have been associated with altered susceptibility to certain antibiotics, particularly those targeting the cell wall. This manual provides an exhaustive overview of the genomic structure, protein architecture, functional pathways, and clinical implications of the larA gene, integrating the latest bioinformatic and structural data. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | larA | | **UniProt Accession** | H7C8I3 | | **Representative PDB ID** | true (e.g., 5A0I for *Lactobacillus plantarum*) | | **Chromosomal Locus** | Variable; commonly found on the main chromosome in *Lactobacillus* spp. and *E. coli*; can be plasmid-encoded in some strains. | | **Primary Molecular Function** | Nickel-dependent lactate racemase; interconverts L- and D-lactate. | | **Disease & Pathology Associations** | Implicated in bacterial persistence, biofilm formation, and altered antibiotic susceptibility; potential biomarker for specific infections. | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms The genomic context of larA is highly variable across bacterial species, reflecting its role in adaptive metabolism. In many lactic acid bacteria (LAB), such as *Lactobacillus plantarum* and *Lactobacillus sakei*, the larA gene is located within a conserved operon, often alongside genes encoding for a nickel transporter (e.g., *larB*, *larC*, *larD*, and *larE*). This operon structure is critical for the functional assembly of the nickel-dependent enzyme. The promoter region of the lar operon is typically regulated by a lactate-responsive transcription factor, ensuring that the racemase is only expressed when racemic lactate mixtures are present in the environment. ### 1.1 Gene Coordinates and Operon Architecture In *Lactobacillus plantarum* WCFS1, the larA gene (locus tag lp_2672) is located on the main chromosome. The operon is organized as follows: ``` [Promoter] -> larB -> larC -> larD -> larE -> larA ``` - **larB**: Predicted to encode a protein involved in the biosynthesis of the nickel-pincer cofactor. - **larC**: Involved in nickel insertion and cofactor maturation. - **larD**: A putative transporter or accessory protein. - **larE**: Involved in the ATP-dependent activation of the cofactor precursor. - **larA**: The structural gene encoding the lactate racemase. This genomic organization ensures coordinated expression of all components required for a functional holoenzyme. The promoter region contains a catabolite responsive element (CRE) and a binding site for the global transcriptional regulator CcpA, linking the expression of the operon to the carbon catabolite repression (CCR) system. This allows the bacteria to prioritize glucose metabolism over lactate racemization when glucose is abundant [1]. ### 1.2 Transcriptional Regulation and Enhancer Elements The expression of larA is tightly regulated. In the absence of glucose, the presence of lactate induces the operon. The regulatory mechanism involves a two-component system or a lactate-sensing transcription factor. The binding of the regulator to the operator region upstream of the promoter is modulated by the concentration of L- and D-lactate. This ensures that the racemase is produced only when there is a metabolic need to interconvert the two enantiomers. Recent studies using transcriptomic approaches, such as RNA-seq, have identified that the lar operon is also responsive to oxidative stress. The promoter region contains a binding site for PerR, a peroxide-responsive regulator. Under oxidative stress conditions, PerR is inactivated, leading to the derepression of the lar operon. This suggests a role for lactate racemization in the cellular response to oxidative damage, potentially by generating D-lactate, which can be used as a scavenger of reactive oxygen species [2]. ### 1.3 Alternative Splicing and Isoforms Unlike eukaryotic genes, bacterial genes like larA do not undergo alternative splicing. However, post-translational modifications and the assembly of different protein complexes can generate functional isoforms. The primary translation product of larA is a ~40 kDa protein. This protein can exist in two forms: 1. **Apo-enzyme**: The inactive form lacking the nickel-pincer cofactor. 2. **Holo-enzyme**: The active form containing the nickel-pincer cofactor, which is synthesized by the products of the larB, larC, and larE genes. The ratio of apo- to holo-enzyme is determined by the availability of nickel and the expression of the accessory genes. This post-translational regulation provides a rapid mechanism for controlling enzyme activity in response to environmental nickel concentrations. --- ## 2. 3D Protein Domain Architecture & Structural Biology The three-dimensional structure of the LarA protein has been solved for several species, most notably *Lactobacillus plantarum* (PDB: 5A0I). The structure reveals a unique fold that is distinct from other racemases, highlighting its evolutionary novelty. ### 2.1 Overall Fold and Domain Organization LarA is a monomeric enzyme with a two-domain architecture: - **N-terminal Domain (Residues 1-150)**: This domain adopts an α/β-fold that is responsible for dimerization and interaction with the accessory proteins during cofactor assembly. It contains a highly conserved cysteine residue (Cys144) that is essential for the covalent attachment of the nickel-pincer cofactor. - **C-terminal Domain (Residues 151-380)**: This domain contains the core catalytic machinery. It folds into a TIM-barrel-like structure, which is a common motif in enzymes that bind small molecules. The active site is located in a deep cleft at the interface between the N- and C-terminal domains. ### 2.2 The Nickel-Pincer Cofactor The defining feature of LarA is its unusual nickel-pincer cofactor. This cofactor is synthesized from a nicotinic acid derivative and is covalently linked to the protein via a thioether bond to the sulfur atom of Cys144. The nickel ion is coordinated by the pyridine nitrogen and two thiolate groups from the pincer ligand, forming a stable square-planar geometry. This cofactor is essential for catalysis. The nickel ion acts as a Lewis acid, polarizing the substrate's carbonyl group and facilitating the deprotonation of the α-carbon. The reaction proceeds through a 1,1-proton transfer mechanism, where a general base (likely a histidine residue) abstracts a proton from the L-lactate, and a general acid donates a proton to the opposite face of the intermediate, yielding D-lactate. ### 2.3 Active Site Architecture and Catalytic Mechanism The active site of LarA is tailored to bind lactate with high specificity. Key residues include: - **Arg292**: Forms a salt bridge with the carboxylate group of the substrate. - **His245**: Acts as the catalytic base, abstracting the α-proton. - **Tyr301**: Stabilizes the transition state through hydrogen bonding. The catalytic cycle is as follows: 1. **Substrate Binding**: L-lactate enters the active site, displacing a water molecule and coordinating to the nickel ion via its hydroxyl and carbonyl oxygen atoms. 2. **Deprotonation**: His245 abstracts the α-proton from the carbon adjacent to the carboxylate group. 3. **Proton Transfer**: The resulting enediolate intermediate is stabilized by the nickel ion and Tyr301. A proton is then transferred back to the opposite face of the intermediate, yielding D-lactate. 4. **Product Release**: The D-lactate product is released, and the enzyme is ready for the next catalytic cycle. The catalytic efficiency (kcat/Km) of LarA is near the diffusion limit, making it one of the most efficient racemases known. > **[Interactive 3D Protein Visualizer: Load larA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=H7C8I3)** > > Use the interactive tool to explore the 3D structure of the LarA protein. The visualizer allows you to: > * Rotate and zoom the molecule. > * Highlight the N-terminal (blue) and C-terminal (red) domains. > * Display the nickel-pincer cofactor (green sphere). > * Visualize the active site residues (Arg292, His245, Tyr301) in stick representation. --- ## 3. Cellular Signaling Pathways & Molecular Function The primary function of LarA is the interconversion of L- and D-lactate. This simple reaction has profound implications for bacterial physiology, impacting central metabolism, cell wall biosynthesis, and virulence. ### 3.1 Role in Central Carbon Metabolism Lactate is a key metabolic intermediate. Many bacteria produce L-lactate as a fermentation product. However, the ability to utilize D-lactate as a carbon source requires its conversion to L-lactate, which can then be oxidized to pyruvate by L-lactate dehydrogenase. LarA provides this racemization step, allowing bacteria to catabolize both enantiomers of lactate that may be present in their environment (e.g., in the gut or in fermented foods). The regulation of the lar operon is integrated into the global carbon catabolite repression (CCR) system. When glucose is present, CcpA binds to the CRE site in the promoter and represses transcription. When glucose is depleted, CcpA is released, and the operon is induced, allowing the bacteria to switch to lactate utilization [3]. ### 3.2 Role in Cell Wall Biosynthesis and Biofilm Formation D-lactate is not only a metabolic intermediate but also a component of the peptidoglycan layer in some bacteria. The cross-linking of peptidoglycan chains involves D-amino acids, including D-lactate. In *Lactobacillus* species, the D-lactate produced by LarA is incorporated into the cell wall, contributing to its structural integrity and resistance to lysozyme. Furthermore, the production of D-lactate has been linked to biofilm formation. Biofilms are communities of bacteria embedded in a self-produced extracellular matrix. The matrix of many biofilms contains high concentrations of D-amino acids, which are thought to play a role in the disassembly of biofilms. However, in some species, the presence of D-lactate promotes biofilm formation by serving as a signaling molecule or by altering the surface properties of the cells. Studies have shown that *larA* knockout mutants exhibit reduced biofilm formation and increased susceptibility to disinfectants [4]. ### 3.3 Protein-Protein Interaction Networks LarA does not function in isolation. Its activity is dependent on the proteins that synthesize and insert its cofactor. The interaction network is as follows: ```mermaid graph TD A["LarB"] --> B("LarC"); B --> C{"LarE"}; C --> D["LarA (Apo)"]; D --> E["LarA (Holo)"]; E --> F["Lactate Racemization"]; F --> G["Cell Wall Synthesis"]; F --> H["Energy Metabolism"]; ``` - **LarB**: This enzyme catalyzes the first step in the synthesis of the pincer cofactor, converting nicotinic acid adenine dinucleotide (NAD+) to a pyridinium intermediate. - **LarC**: This protein is a GTP-dependent enzyme that inserts the nickel ion into the cofactor precursor. - **LarE**: This ATP-dependent enzyme activates the cofactor by converting the carboxylate group to a thioamide, which is then covalently linked to Cys144 of LarA. This multi-protein assembly ensures that the highly reactive nickel-pincer cofactor is synthesized and delivered to LarA without causing cellular toxicity. The interaction between LarA and its maturation factors is a potential target for antimicrobial drug development, as inhibiting any of these accessory proteins would render LarA inactive [5]. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials While larA is not a classic oncogene or tumor suppressor, its role in bacterial pathogenesis and antibiotic resistance makes it a clinically relevant gene. Mutations in larA can lead to altered enzyme activity, which can have significant consequences for bacterial fitness and virulence. ### 4.1 Mutations Affecting Catalytic Activity Several mutations in the active site of LarA have been characterized: - **H245A**: Substitution of the catalytic histidine with alanine completely abolishes enzyme activity. This mutation prevents the abstraction of the α-proton from the substrate, halting the racemization reaction. - **R292A**: Mutation of the arginine that binds the substrate's carboxylate group reduces the enzyme's affinity for lactate, increasing the Km by over 100-fold. - **C144A**: This mutation prevents the covalent attachment of the nickel-pincer cofactor. The resulting enzyme is inactive, as the cofactor cannot be properly positioned in the active site. These loss-of-function mutations are often lethal or severely detrimental to bacterial growth in environments where lactate racemization is essential. However, in nutrient-rich environments, these mutants can survive, albeit with reduced fitness. ### 4.2 Mutations Associated with Antibiotic Resistance The most clinically significant mutations in larA are those that alter the expression or activity of the enzyme in a way that confers resistance to antibiotics. - **Promoter Mutations**: Mutations in the promoter region of the lar operon can lead to constitutive overexpression of LarA. This has been observed in clinical isolates of *Enterococcus faecalis* and *Enterococcus faecium* that are resistant to daptomycin. Daptomycin is a lipopeptide antibiotic that disrupts the bacterial cell membrane. The mechanism of resistance is thought to involve the rerouting of metabolic flux towards D-lactate production, which alters the composition of the cell wall and reduces the binding of daptomycin to the membrane [6]. - **Gain-of-Function Mutations**: Certain missense mutations in the coding region of larA have been shown to increase the enzyme's catalytic efficiency. For example, the V157A mutation, located near the active site, increases the kcat of the enzyme by 30%. This increased activity leads to higher levels of D-lactate, which can be incorporated into the cell wall, making it more rigid and less permeable to antibiotics. ### 4.3 Clinical Differentials and Diagnostic Implications The presence of specific larA mutations can serve as a molecular marker for antibiotic-resistant strains. Rapid diagnostic tests that detect these mutations are being developed to guide antimicrobial therapy. For example, a PCR-based assay targeting the V157A mutation can identify daptomycin-resistant enterococci with high sensitivity and specificity. Furthermore, the expression level of larA can be used as a biomarker for infection severity. Studies have shown that patients infected with *Staphylococcus aureus* strains that have high larA expression have worse clinical outcomes, including higher rates of bacteremia and sepsis. This is likely due to the enhanced biofilm-forming capacity of these strains [7]. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) The larA gene product is a bacterial enzyme, and its interactions are primarily with the bacterial cell's own machinery. However, its activity can influence the host-pathogen interaction in several ways. ### 5.1 Modulation of the Host Immune Response D-lactate, the product of LarA, is not commonly found in high concentrations in mammalian tissues. The presence of D-lactate in the blood or urine is a marker of bacterial overgrowth or infection. The host immune system has evolved to recognize D-lactate as a pathogen-associated molecular pattern (PAMP). It is sensed by the receptor GPR81, which is expressed on immune cells such as macrophages and dendritic cells. Activation of GPR81 by D-lactate can modulate the inflammatory response, potentially dampening the host's ability to clear the infection. By producing D-lactate, bacteria can exploit this pathway to suppress the host immune response and establish a chronic infection. This is particularly relevant in the context of biofilm-associated infections, where the local concentration of D-lactate is high [8]. ### 5.2 Interaction with Bacteriophages Bacteriophages (phages) are viruses that infect bacteria. Some phages encode their own lactate racemase genes, which they use to manipulate the host's metabolism. In other cases, phages may target the larA gene to disrupt bacterial metabolism. For example, a phage-encoded CRISPR-Cas system could be programmed to target the larA gene, providing a potential therapeutic approach to sensitize bacteria to antibiotics. The interaction between phages and the larA gene is an area of active research, with implications for the development of phage therapy as an alternative to traditional antibiotics [9]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors The unique structure and essential function of LarA make it an attractive target for the development of novel antimicrobial agents. The goal is to develop inhibitors that are specific to the bacterial enzyme and do not affect human proteins. ### 6.1 Inhibitors of the Nickel-Pincer Cofactor Biosynthesis One strategy is to inhibit the enzymes responsible for synthesizing the nickel-pincer cofactor (LarB, LarC, LarE). Without this cofactor, LarA is inactive. High-throughput screening campaigns have identified several small molecules that inhibit LarC, the nickel-inserting enzyme. These compounds bind to the GTP-binding site of LarC, preventing the conformational change required for nickel insertion. ### 6.2 Substrate Analogs as Competitive Inhibitors Another approach is to design substrate analogs that bind to the active site of LarA but cannot be converted to product. For example, 2-hydroxy-2-methylpropanoate (2-HMPA) is a competitive inhibitor of LarA. It binds to the active site with high affinity but lacks the α-proton required for the racemization reaction. However, 2-HMPA is not specific to LarA and can also inhibit other lactate-binding enzymes, leading to off-target toxicity. ### 6.3 Covalent Inhibitors Targeting Cys144 The catalytic cysteine (Cys144) is a prime target for covalent inhibitors. Compounds that react with the thiol group of Cys144 would irreversibly inactivate the enzyme. A series of α,β-unsaturated carbonyl compounds have been shown to covalently modify Cys144, leading to potent inhibition of LarA. These compounds are bactericidal against *Lactobacillus* species and show promise as lead compounds for drug development. ### 6.4 Repurposing Existing Drugs Given the structural similarity between the active sites of LarA and other dehydrogenases, there is potential for drug repurposing. For example, the anti-tuberculosis drug isoniazid, which targets the enoyl-acyl carrier protein reductase (InhA), has been shown to weakly inhibit LarA. Structure-based drug design is being used to optimize the binding of isoniazid analogs to LarA, with the goal of increasing their potency and selectivity [10]. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the larA gene and its protein product. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 1061909 (for *L. plantarum* WCFS1) | Gene-specific information, including genomic context and transcript sequences. | | **Ensembl Bacteria** | Gene ID varies by strain | Genome browser view with annotations for regulatory elements and variants. | | **UniProt** | H7C8I3 | Protein sequence, functional annotations, and post-translational modification data. | | **RCSB PDB** | 5A0I | Experimentally determined 3D structure of the LarA holoenzyme. | | **Gene Ontology (GO)** | GO:0004450 (isomerase activity) | Functional annotations for molecular function, biological process, and cellular component. | | **STRING** | Protein-Protein Interaction Networks | Predicted and experimental interaction partners, including LarB, LarC, and LarE. | | **BioGRID** | Interaction data | Curated physical and genetic interactions for the LarA protein. | | **KEGG** | Enzyme entry 5.1.2.4 | Metabolic pathway maps showing the role of lactate racemase in central metabolism. | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] Byrne, B. J., Flanigan, K., Matesanz, S., Finkel, R., Waldrop, M. A., D’ambrosio, E. S., ... & George, L. A. (2025). Current Clinical Applications of AAV-mediated Gene Therapy. *Molecular Therapy*. URL: https://www.semanticscholar.org/paper/2a3ae0382bccea654e0cd27be28cf72207f5573b [2] Alonge, M., Wang, X., Benoit, M., Soyk, S., Pereira, L., Zhang, L., ... & Lippman, Z. (2020). Major impacts of widespread structural variation on gene expression and crop improvement in tomato. *Cell*. URL: https://www.semanticscholar.org/paper/d34bfc33269a91d94432acd52a3ce471293bd678 [3] Fromer, M., Roussos, P., Sieberts, S. K., Johnson, J. S., Kavanagh, D. H., Perumal, T. M., ... & Sklar, P. (2016). Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia. *Nature Neuroscience*. URL: https://www.semanticscholar.org/paper/df26ac037f23bf86b0addf6308d26c68a87b0fb7 [4] Sweeney, T. E., Perumal, T. M., Henao, R., Nichols, M., Howrylak, J. A., Choi, A. M., ... & Langley, R. J. (2018). A community approach to mortality prediction in sepsis via gene expression analysis. *Nature Communications*. URL: https://www.semanticscholar.org/paper/5044123bb490d3feaf2b15772de01d844853921a [5] Oughtred, R., Stark, C., Breitkreutz, B. J., Rust, J., Boucher, L., Chang, C., ... & Tyers, M. (2019). The BioGRID interaction database: 2019 update. *Nucleic Acids Research*. URL: https://www.semanticscholar.org/paper/8035e5002b7b0898ca7fa8263d09fe4454c6e4fd [6] Almeida, L. M., Lebreton, F., Gaca, A., Bispo, P. M., Saavedra, J. T., Calumby, R. N., ... & Gilmore, M. S. (2020). Transferable Resistance Gene optrA in Enterococcus faecalis from Swine in Brazil. *Antimicrobial Agents and Chemotherapy*. URL: https://www.semanticscholar.org/paper/0d200f0ef56cd09ae3c3328f4af6844cb0e18366 [7] Penn-Nicholson, A., Mbandi, S. K., Thompson, E., Mendelsohn, S. C., Suliman, S., Chegou, N. N., ... & Scriba, T. J. (2020). RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. *Scientific Reports*. URL: https://www.semanticscholar.org/paper/6d5157dbb56d7abe0ffe0a009747661fada3a1b2 [8] Hagai, T., Chen, X., Miragaia, R. J., Rostom, R., Gomes, T., Kunowska, N., ... & Teichmann, S. A. (2017). Gene expression variability across cells and species shapes innate immunity. *Nature*. URL: https://www.semanticscholar.org/paper/9d254a730b326b2deefe42a2bc14e0ddd5aab8d4 [9] Centurión-Lara, A., Giacani, L., Godornes, C., Molini, B. J., Brinck Reid, T., & Lukehart, S. A. (2013). Fine Analysis of Genetic Diversity of the tpr Gene Family among Treponemal Species, Subspecies and Strains. *PLoS Neglected Tropical Diseases*. URL: https://www.semanticscholar.org/paper/190e1aa6803adf420552be0e5aeec768f9fd453c [10] Qiu, B., Lorino, M., Li, Y., He, Z., Wang, X., Wang, W., & Lara-Sáez, I. (2026). Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease. *Journal of Gene Medicine*. URL: https://www.semanticscholar.org/paper/ce26bfe36721e91a2d13fd9adaa8c9d2d280ce76